<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="article-commentary"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Front Psychiatry</journal-id><journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id><journal-title-group><journal-title>Frontiers in Psychiatry</journal-title></journal-title-group><issn pub-type="epub">1664-0640</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28469583</article-id><article-id pub-id-type="pmc">5395636</article-id><article-id pub-id-type="doi">10.3389/fpsyt.2017.00059</article-id><article-categories><subj-group subj-group-type="heading"><subject>Psychiatry</subject><subj-group><subject>General Commentary</subject></subj-group></subj-group></article-categories><title-group><article-title>Commentary: A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin Treatment of Weight Gain Associated with Initiation of Atypical Antipsychotic Therapy in Children and Adolescents</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Goltz</surname><given-names>Jeffrey Samuel</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/408046"/></contrib><contrib contrib-type="author"><name><surname>Rice</surname><given-names>Timothy Reynolds</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/153647"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Psychiatry, Mount Sinai St. Luke&#x02019;s-West Hospital</institution>, <addr-line>New York City, NY</addr-line>, <country>USA</country></aff><aff id="aff2"><sup>2</sup><institution>Psychiatry, Icahn School of Medicine at Mount Sinai</institution>, <addr-line>New York City, NY</addr-line>, <country>USA</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Susan DosReis, University of Maryland Baltimore, USA</p></fn><fn fn-type="edited-by"><p>Reviewed by: Justine Larson, Johns Hopkins School of Medicine, USA; Gloria Reeves, University of Maryland Baltimore, USA</p></fn><corresp content-type="corresp" id="cor1">*Correspondence: Jeffrey Samuel Goltz, <email>jeffrey.goltz@mountsinai.org</email>; Timothy Reynolds Rice, <email>timothy.rice@mountsinai.org</email></corresp><fn fn-type="other" id="fn002"><p>Specialty section: This article was submitted to Child and Adolescent Psychiatry, a section of the journal Frontiers in Psychiatry</p></fn></author-notes><pub-date pub-type="epub"><day>19</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>8</volume><elocation-id>59</elocation-id><history><date date-type="received"><day>30</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>31</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 Goltz and Rice.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Goltz and Rice</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><related-article id="d35e138" related-article-type="commentary-article" xlink:href="17151157" ext-link-type="pubmed" journal-id="Am J Psychiatry" journal-id-type="nlm-ta" vol="163" page="2072">A commentary on <article-title>A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin Treatment of Weight Gain Associated with Initiation of Atypical Antipsychotic Therapy in Children and Adolescents</article-title> by Klein D, Cottingham E, Sorter M, Barton BA, Morrison JA. Am J Psychiatry (2006) 163(12):2072&#x02013;9. doi:<object-id>10.1176/ajp.2006.163.12.2072</object-id></related-article><kwd-group><kwd>metformin</kwd><kwd>atypical antipsychotics</kwd><kwd>children and adolescents</kwd><kwd>obesity</kwd><kwd>weight gain</kwd></kwd-group><counts><fig-count count="0"/><table-count count="0"/><equation-count count="0"/><ref-count count="19"/><page-count count="3"/><word-count count="1864"/></counts></article-meta></front><body><sec sec-type="introduction" id="S1"><title>Introduction</title><p>In 2006, Klein and colleagues conducted the first randomized control trial (RCT) to analyze the benefit of adding metformin to treat weight gain induced by second-generation antipsychotics (SGAs) in children and adolescents (<xref rid="B1" ref-type="bibr">1</xref>). In this commentary, I review this study, the relationship between childhood obesity and SGA weight gain, and current methods for treating SGA-induced weight gain to better elucidate this trial&#x02019;s significance.</p></sec><sec id="S2"><title>Introduction to Childhood Obesity</title><p>Youth obesity has reached epidemic proportions around the world. Obesity impacts both youth physical and mental health. Overweight habitus creates multiple physical limitations, increases the incidence of multiple medical comorbidities including diabetes and hypertension, and raises the rates of morbidity and mortality at adulthood (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>). In addition, obesity has been associated with increased economic costs and various impairments in mental health, including a decrease in self-esteem (<xref rid="B4" ref-type="bibr">4</xref>), ADHD, depression (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>), eating disorders (<xref rid="B4" ref-type="bibr">4</xref>), and increased rates of stigmatization (<xref rid="B2" ref-type="bibr">2</xref>).</p></sec><sec id="S3"><title>Weight Gain Induced by SGAs</title><p>Second-generation antipsychotics are used for the treatment of mania, psychosis, depression, impulsivity, and aggression in children and adolescents (<xref rid="B6" ref-type="bibr">6</xref>). While weight gain in all age groups is a common adverse drug effect, youth are more vulnerable to this effect relative to adults (<xref rid="B7" ref-type="bibr">7</xref>). For example, aripiprazole, considered by some to be weight neutral in adults, causes significant weight gain in children and adolescents (<xref rid="B7" ref-type="bibr">7</xref>). SGA-induced weight gain contributes to non-compliance with medication (<xref rid="B8" ref-type="bibr">8</xref>). For these and other reasons, behavioral and medicinal means to reduce the extent of weight gain are under active investigation.</p></sec><sec id="S4"><title>Evidence for Lifestyle Interventions for Weight Loss</title><p>The positive effects of lifestyle interventions on reducing SGA-induced weight gain and on overall mental health make them an attractive treatment option. A brief description of some of the evidence for the efficacy of lifestyle interventions will be provided. A recent meta-analysis of adults has indirectly demonstrated that the amount of weight loss due to lifestyle interventions may be similar to that provided by use of pharmaceutical agents (<xref rid="B9" ref-type="bibr">9</xref>). Though contradictory findings exist, including a study (<xref rid="B10" ref-type="bibr">10</xref>) in which medication alone was more effective for weight loss than behavioral interventions, it is possible that this study reflects the difficulty of many psychiatric patients to adhere to strict dietary guidelines or exercise regimens, including those used in behavioral interventions (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>). This is one reason that medications like metformin are being studied.</p></sec><sec id="S5"><title>Metformin as a Medication for Weight Loss</title><p>Metformin is a biguanide antidiabetic agent. Multiple mechanisms have been proposed for its effect on weight loss. These include its ability to decrease insulin resistance (reversing the insulin resistance caused by antipsychotics) and reduce hepatic glucose production (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>). While multiple RCTs and meta-analyses show metformin to be moderately beneficial for promoting weight loss in adults using antipsychotics, others found no weight loss benefits (<xref rid="B13" ref-type="bibr">13</xref>&#x02013;<xref rid="B15" ref-type="bibr">15</xref>). The weight-reducing potential of metformin in non-diabetic, overweight children, and adolescents has been previously demonstrated (<xref rid="B16" ref-type="bibr">16</xref>). Metformin&#x02019;s efficacy in treating antipsychotic-induced weight gain in youth has been examined in open label trials and case reports (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B17" ref-type="bibr">17</xref>). However, only three RCTs examining its efficacy in treating antipsychotic-induced weight gain in children have been published (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B18" ref-type="bibr">18</xref>).</p></sec><sec id="S6"><title>Klein&#x02019;s RCT</title><p>Klein et al. (<xref rid="B1" ref-type="bibr">1</xref>) was the first RCT to examine metformin&#x02019;s weight-reducing potential in children receiving antipsychotic medication. Thirty-eight children with varying psychiatric diagnoses aged 10&#x02013;17 on one SGA for less than 12&#x02009;months (olanzapine, risperidone, or quetiapine) and exhibiting weight gains greater than 10% of their predrug weight were randomized to receive either metformin (850&#x02009;mg BID after titration) or placebo. A dietician assessed all subjects and counseled them in improving their diet and exercise regimens. Primary outcome measures were changes in weight and body mass index (BMI) over a 16-week period. The metformin-treated group showed minimal weight (mean&#x02009;=&#x02009;&#x02212;0.13&#x02009;kg, SD&#x02009;=&#x02009;2.88) and BMI (mean&#x02009;=&#x02009;&#x02212;0.43, SD&#x02009;=&#x02009;1.07) changes, compared to those in the placebo group who gained on average 4.01&#x02009;kg (SD&#x02009;=&#x02009;6.23) and mean increases of 1.12 (SD&#x02009;=&#x02009;2.02) in BMI. When correcting for expected weight gain in developing children, the final <italic>z</italic>-score was 1.72 (SD&#x02009;=&#x02009;0.99) for the placebo group&#x02019;s weight change and 0.09 (SD&#x02009;=&#x02009;0.25) for BMI, versus <italic>z</italic>-score of &#x02212;0.14 (SD&#x02009;=&#x02009;0.29) and &#x02212;0.14 (SD&#x02009;=&#x02009;0.20), respectively, in the metformin-treated group. These results were statistically significant. Also the rate of children with an indication for a glucose tolerance test was greater in the placebo group (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01), and consequently, more children taking placebo had impaired glucose tolerance. There was no significant difference in rates of adverse events.</p></sec><sec id="S7"><title>Subsequent Studies</title><p>Anagnostou et al. (<xref rid="B11" ref-type="bibr">11</xref>) subsequently examined the impact of metformin on weight reduction in 61 children (ages 6&#x02013;17) with autism spectrum disorder taking various SGAs. This study found that metformin was more effective than placebo in treating antipsychotic-induced weight gain. In contrast, Arman et al. (<xref rid="B18" ref-type="bibr">18</xref>) failed to establish the efficacy of using metformin to prevent weight gain in a study of 32 children/adolescents with schizophrenia or schizoaffective disorder receiving both risperidone and metformin versus placebo in a 12-week RCT trial.</p></sec><sec id="S8"><title>Conclusion</title><p>Thus, data from existing RCT-based studies for evaluating the benefits of using metformin to reduce antipsychotic-induced weight gain in youth have been contradictory. Existing data have limitations, including small sample size, inconsistent cross-study methodologies, and limited time frames. Larger and more longitudinal RCTs are needed and are currently underway [see IMPACT trial by Reeves et al. (<xref rid="B19" ref-type="bibr">19</xref>)] and will likely shed more light on the efficacy of using metformin for treatment and prevention of SGA-induced weight gain in youth.</p></sec><sec id="S9"><title>Author Contributions</title><p>JG&#x02014;substantial contribution to designing the work, acquisition of information, drafted and revised the work, approved final version, and agreed to be accountable for all aspects of the work. TR&#x02014;substantial contribution to designing and outlining the work, revised it for important intellectual content, approved final version, and agreed to be accountable for all aspects of the work.</p></sec><sec id="S10"><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer, GR, and handling editor declared their shared affiliation, and the handling editor states that the process nevertheless met the standards of a fair and objective review.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>D</given-names></name><name><surname>Cottingham</surname><given-names>E</given-names></name><name><surname>Sorter</surname><given-names>M</given-names></name><name><surname>Barton</surname><given-names>BA</given-names></name><name><surname>Morrison</surname><given-names>JA</given-names></name></person-group>. <article-title>A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents</article-title>. <source>Am J Psychiatry</source> (<year>2006</year>) <volume>163</volume>(<issue>12</issue>):<fpage>2072</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1176/ajp.2006.163.12.2072</pub-id><pub-id pub-id-type="pmid">17151157</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bean</surname><given-names>MK</given-names></name><name><surname>Stewart</surname><given-names>K</given-names></name><name><surname>Olbrisch</surname><given-names>ME</given-names></name></person-group>. <article-title>Obesity in America: implications for clinical and health psychologists</article-title>. <source>J Clin Psychol Med Settings</source> (<year>2008</year>) <volume>15</volume>(<issue>3</issue>):<fpage>214</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="doi">10.1007/s10880-008-9124-9</pub-id><pub-id pub-id-type="pmid">19104966</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swallen</surname><given-names>KC</given-names></name><name><surname>Reither</surname><given-names>EN</given-names></name><name><surname>Haas</surname><given-names>SA</given-names></name><name><surname>Meier</surname><given-names>AM</given-names></name></person-group>. <article-title>Overweight, obesity, and health-related quality of life among adolescents: the national longitudinal study of adolescent health</article-title>. <source>Pediatrics</source> (<year>2005</year>) <volume>115</volume>(<issue>2</issue>):<fpage>340</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1542/peds.2004-0678</pub-id><pub-id pub-id-type="pmid">15687442</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rankin</surname><given-names>J</given-names></name><name><surname>Matthews</surname><given-names>L</given-names></name><name><surname>Cobley</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>A</given-names></name><name><surname>Sanders</surname><given-names>R</given-names></name><name><surname>Wiltshire</surname><given-names>HD</given-names></name><etal/></person-group>
<article-title>Psychological consequences of childhood obesity: psychiatric comorbidity and prevention</article-title>. <source>Adolesc Health Med Ther</source> (<year>2016</year>) <volume>7</volume>:<fpage>125</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="doi">10.2147/AHMT.S101631</pub-id><pub-id pub-id-type="pmid">27881930</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halfon</surname><given-names>N</given-names></name><name><surname>Larson</surname><given-names>K</given-names></name><name><surname>Slusser</surname><given-names>W</given-names></name></person-group>. <article-title>Associations between obesity and comorbid mental health, developmental, and physical health conditions in a nationally representative sample of us children aged 10 to 17</article-title>. <source>Acad Pediatr</source> (<year>2013</year>) <volume>13</volume>(<issue>1</issue>):<fpage>6</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1016/j.acap.2012.10.007</pub-id><pub-id pub-id-type="pmid">23200634</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Shatkin</surname><given-names>JP</given-names></name></person-group>
<source>Child and Adolescent Mental Health: A Practical, All-in-One Guide</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Norton</publisher-name> (<year>2015</year>).</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Ortega</surname><given-names>JM</given-names></name><name><surname>Funes-Godoy</surname><given-names>S</given-names></name><name><surname>Diaz-Atienza</surname><given-names>F</given-names></name><name><surname>Gutierrez-Rojas</surname><given-names>L</given-names></name><name><surname>Perez-Costillas</surname><given-names>L</given-names></name><name><surname>Gurpegui</surname><given-names>M</given-names></name></person-group>
<article-title>Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review</article-title>. <source>Eur Child Adolesc Psychiatry</source> (<year>2013</year>) <volume>22</volume>(<issue>8</issue>):<fpage>457</fpage>&#x02013;<lpage>79</lpage>.<pub-id pub-id-type="doi">10.1007/s00787-013-0399-5</pub-id><pub-id pub-id-type="pmid">23503976</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lieberman</surname><given-names>J</given-names></name><name><surname>Stroup</surname><given-names>T</given-names></name><name><surname>McEvoy</surname><given-names>J</given-names></name><name><surname>Swartz</surname><given-names>M</given-names></name><name><surname>Rosenheck</surname><given-names>R</given-names></name><name><surname>Perkins</surname><given-names>DO</given-names></name><etal/></person-group>
<article-title>Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</article-title>. <source>N Engl J Med</source> (<year>2005</year>) <volume>353</volume>(<issue>12</issue>):<fpage>1209</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMoa051688</pub-id><pub-id pub-id-type="pmid">16172203</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caemmerer</surname><given-names>J</given-names></name><name><surname>Correll</surname><given-names>CU</given-names></name><name><surname>Maayan</surname><given-names>L</given-names></name></person-group>. <article-title>Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials</article-title>. <source>Schizophr Res</source> (<year>2012</year>) <volume>140</volume>(<issue>1&#x02013;3</issue>):<fpage>159</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2012.03.017</pub-id><pub-id pub-id-type="pmid">22763424</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>R-R</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Shao</surname><given-names>P</given-names></name><name><surname>Fang</surname><given-names>M-S</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Lifestyle intervention and metformin for treatment of antipsychotic-induced</article-title>. <source>JAMA</source> (<year>2008</year>) <volume>299</volume>(<issue>2</issue>):<fpage>185</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="doi">10.1001/jama.2007.56-b</pub-id><pub-id pub-id-type="pmid">18182600</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anagnostou</surname><given-names>E</given-names></name><name><surname>Aman</surname><given-names>MG</given-names></name><name><surname>Handen</surname><given-names>BL</given-names></name><name><surname>Sanders</surname><given-names>KB</given-names></name><name><surname>Shui</surname><given-names>A</given-names></name><name><surname>Hollway</surname><given-names>JA</given-names></name><etal/></person-group>
<article-title>Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder a randomized clinical trial</article-title>. <source>JAMA Psychiatry</source> (<year>2016</year>) <volume>73</volume>(<issue>9</issue>):<fpage>928</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2016.1232</pub-id><pub-id pub-id-type="pmid">27556593</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermansen</surname><given-names>K</given-names></name><name><surname>Mortensen</surname><given-names>LS</given-names></name></person-group>
<article-title>Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus</article-title>. <source>Drug Saf</source> (<year>2007</year>) <volume>30</volume>(<issue>12</issue>):<fpage>1127</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="doi">10.2165/00002018-200730120-00005</pub-id><pub-id pub-id-type="pmid">18035865</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bj&#x000f6;rkhem-Bergman</surname><given-names>L</given-names></name><name><surname>Asplund</surname><given-names>AB</given-names></name><name><surname>Lindh</surname><given-names>JD</given-names></name></person-group>
<article-title>Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis</article-title>. <source>J Psychopharmacol</source> (<year>2011</year>) <volume>25</volume>(<issue>3</issue>):<fpage>299</fpage>&#x02013;<lpage>305</lpage>.<pub-id pub-id-type="doi">10.1177/0269881109353461</pub-id><pub-id pub-id-type="pmid">20080925</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Jeong</surname><given-names>JH</given-names></name></person-group>. <article-title>A systematic review of metformin to limit weight-gain with atypical antipsychotics</article-title>. <source>J Clin Pharm Ther</source> (<year>2011</year>) <volume>36</volume>(<issue>5</issue>):<fpage>537</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2710.2011.01255.x</pub-id><pub-id pub-id-type="pmid">21418264</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>X-B</given-names></name><name><surname>Tang</surname><given-names>Y-L</given-names></name><name><surname>Xiang</surname><given-names>Y-Q</given-names></name><name><surname>Wang</surname><given-names>C-Y</given-names></name><name><surname>de Leon</surname><given-names>J</given-names></name></person-group>. <article-title>Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials</article-title>. <source>J Clin Psychopharmacol</source> (<year>2015</year>) <volume>35</volume>(<issue>5</issue>):<fpage>499</fpage>&#x02013;<lpage>509</lpage>.<pub-id pub-id-type="doi">10.1097/JCP.0000000000000392</pub-id><pub-id pub-id-type="pmid">26280837</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanovski</surname><given-names>JA</given-names></name><name><surname>Krakoff</surname><given-names>J</given-names></name><name><surname>Salaita</surname><given-names>CG</given-names></name><name><surname>McDuffie</surname><given-names>JR</given-names></name><name><surname>Kozlosky</surname><given-names>M</given-names></name><name><surname>Sebring</surname><given-names>NG</given-names></name><etal/></person-group>
<article-title>Effects of metformin on body weight and body composition in obese insulin-resistant children a randomized clinical trial</article-title>. <source>Diabetes</source> (<year>2011</year>) <volume>60</volume>(<issue>2</issue>):<fpage>477</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="doi">10.2337/db10-1185</pub-id><pub-id pub-id-type="pmid">21228310</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salau</surname><given-names>M</given-names></name><name><surname>Adam</surname><given-names>B</given-names></name><name><surname>Coffey</surname><given-names>BJ</given-names></name></person-group>
<article-title>Metformin in an adolescent with significant weight gain</article-title>. <source>J Child Adolesc Psychopharmacol</source> (<year>2015</year>) <volume>25</volume>(<issue>7</issue>):<fpage>589</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="doi">10.1089/cap.2015.29022.bjc</pub-id><pub-id pub-id-type="pmid">26375769</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arman</surname><given-names>S</given-names></name><name><surname>Sadramely</surname><given-names>MR</given-names></name><name><surname>Nadi</surname><given-names>M</given-names></name><name><surname>Koleini</surname><given-names>N</given-names></name></person-group>. <article-title>A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents</article-title>. <source>Saudi Med J</source> (<year>2008</year>) <volume>29</volume>(<issue>8</issue>):<fpage>1130</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">18690305</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reeves</surname><given-names>GM</given-names></name><name><surname>Keeton</surname><given-names>C</given-names></name><name><surname>Correll</surname><given-names>CU</given-names></name><name><surname>Johnson</surname><given-names>JL</given-names></name><name><surname>Hamer</surname><given-names>RM</given-names></name><name><surname>Sikich</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods</article-title>. <source>Child Adolesc Psychiatry Ment Health</source> (<year>2013</year>) <volume>7</volume>(<issue>1</issue>):<fpage>31</fpage>.<pub-id pub-id-type="doi">10.1186/1753-2000-7-31</pub-id><pub-id pub-id-type="pmid">23947389</pub-id></mixed-citation></ref></ref-list></back></article>